Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer.
Of 57 patients treated, 48 percent responded to the...
More From BioPortfolio on "Promising clinical trial results of tucatinib with T-DM1 against HER2 breast cancer"